Background and objective: The role of non-invasive ventilation (NIV) during exercise training (ET) in patients with chronic respiratory failure (CRF) is still unclear. The aim of this study was to test whether NIV during ET had an additional effect in increasing the 6-min walking distance (6MWD) and cycle endurance time compared with ET alone. Methods: All patients underwent 20 sessions of cycle training over 3 weeks and were randomly assigned to ET with NIV or ET alone. Outcome measures were 6MWD (primary outcome), incremental and endurance cycle ergometer exercise time, respiratory muscle function, quality of life by the Maugeri Respiratory Failure questionnaire (MRF-28), dyspnoea (Medical Research Council scale) and leg fatigue at rest. Results: Forty-two patients completed the study. Following training, no significant difference in 6MWD changes were found between groups. Improvement in endurance time was significantly greater in the NIV group compared with the non-NIV training group (754 AE 973 vs 51 AE 406 s, P = 0.0271); dyspnoea improved in both groups, while respiratory muscle function and leg fatigue improved only in the NIV ET group. MRF-28 improved only in the group training without NIV. Conclusion: In CRF patients on long-term NIV and long-term oxygen therapy (LTOT), the addition of NIV to ET sessions resulted in an improvement in endurance time, but not in 6MWD.
INTRODUCTION
Pulmonary rehabilitation, mainly based on exercise training (ET), is a recognized core component of managing patients with respiratory disorders, including those suffering from chronic respiratory failure (CRF). 1, 2 The use of non-invasive ventilation (NIV) as an aid to ET has been suggested, 3, 4 and two recent meta-analyses concluded there was a need for further randomized clinical trials. 5, 6 Severe stable chronic obstructive pulmonary disease (COPD) patients undergoing home nocturnal NIV and daytime ET show a significant improvement in exercise capacity and health-related quality of life (HRQL) as compared with patients undergoing ET alone. [7] [8] [9] Similar results have been reported in patients with interstitial lung 10 and restrictive thoracic diseases (RTD). 11, 12 Furthermore, in chronic hypercapnic COPD patients under long-term ventilatory support, NIV can be administered during walking, resulting in improved oxygenation, 13 decreased dyspnoea and increased walking distance. 14 The most recent joint American Thoracic (ATS)/European Respiratory (ERS) Societies pulmonary rehabilitation statement 1 concluded that NIV during ET is 'difficult and labour-intensive', and may only be feasible in specialist units. In particular, NIV during ET may be difficult in naïve patients not accustomed to the NIV mask and the positive pressure. It is possible that patients with CRF, due to either COPD or RTD, on long-term NIV would benefit from exercising with NIV as they are already familiar with the ventilator and interface.
The aim of this study was to investigate if adding NIV during ET sessions increased 6-min walking distance (6MWD) compared with ET alone in patients with CRF on NIV and long-term oxygen therapy (LTOT). Secondary outcomes were symptomatic improvement, respiratory muscle function HRQL and exercise endurance time.
METHODS
This multicentre randomized controlled trial (RCT) was conducted from April 2012 to April 2016 in. Istituti Clinici Scientifici Maugeri Lumezzane (Italy); Auxilium Vitae Volterra (Italy); Fondazione Don Gnocchi IRCCS, Firenze (Italy); and Pulmonary Rehabilitation and Home Care Center, Ataturk, Ankara (Turkey). The RCT was approved by the Ethics Committee (CE 667) of Istituti Clinici Scientifici Maugeri and registered at clinicaltrials.gov (NCT01458314). Written informed consent to participate was obtained from all participants.
Study participants
Patients, 40-80 years old, with chronic hypercapnia and hypoxaemia due to either COPD or RTD, on longterm nocturnal NIV according to current guidelines, 15 and LTOT for at least 6 months, attending an in-patient rehabilitation programme were eligible for the study. Patients were enrolled if in a stable clinical condition (no exacerbation in the 4 weeks prior to study together with an arterial pH > 7.35) and without any of the following exclusion criteria: ischaemic cardiac disease, chronic heart failure, orthopaedic and/or neuromuscular diseases limiting exercise, refusal to participate or participation in a pulmonary rehabilitation programme during the previous 6 months.
Study design
Eligible patients were selected from participating centres and enrolled to an in-patient rehabilitation programme. Patients were randomly assigned to study groups (group 1: ET sessions with NIV) or control group (group 2: ET alone) by centralized block balanced randomization performed by a statistician not involved in the study. Consecutive patients were enrolled independent of the cause of CRF and researchers evaluating results were blinded to the intervention received.
Patients maintained their usual drugs medication, setting of nocturnal NIV and LTOT flow rate during the entire study.
Training sessions
The ET programme included 20 sessions over a 3-week period consisting of: 
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NIV setting
In group 1, NIV was performed during ET sessions with the same ventilator, mask and, at the start of exercise, settings used at home by each patient. In case of discomfort during exercise, changes to ventilator settings were adjusted to patient comfort allowed by increasing or decreasing inspiratory (IPAP) and/or expiratory (EPAP) positive airway pressures.
Measurements
At admission, an independent blinded assessor not involved in the study recorded the following assessments:
• Demographic, anthropometric [age and body mass index (BMI)], clinical (diagnosis according to two subgroups: COPD or RTD and co-morbidities, dyspnoea) and physiological characteristics of the patients.
• Co-morbidities, evaluated by means of the Cumulative Illness Rating Scale (CIRS).
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• Dyspnoea, assessed by means of the Medical Research Council (MRC) scale.
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• Static and dynamic lung volumes, assessed after bronchodilation and expressed as absolute and percent of predicted values according to Quanier et al.
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• Arterial blood gases, assessed while patients breathed room air or their usual oxygen flow in the sitting position.
Before (T0) and after the rehabilitation programme (T1), patients underwent evaluation of the following outcome measures under spontaneous breathing:
• Exercise tolerance, assessed by means of:
1. The 6MWD test according to the ATS guidelines. 21 At the beginning and end of the test, subjective sensations of dyspnoea and leg fatigue were assessed by means of the modified Borg scale. 
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• HRQL, evaluated by means of the Maugeri Respiratory Failure questionnaire (MRF-28), specifically designed for patients with CRF. 25 
Statistical analysis
The primary study outcome measure was the 6MWD.
Results are shown as mean (SD) for continuous and as percentage for categorical or binary variables.
To determine the sample size, a preliminary evaluation showed a post-NIV-aided ET mean improvement in 6MWD of 49 (25) m. Data about exploratory sample of patients trained with NIV are outlined in Table S1 (Supplementary Information). For controls, we used the reported 25 (25) m improvement after training without NIV. 26 The study hypothesis was therefore to observe a post-ET change of 50 (25) in group 1 as compared with a post-ET change of 25 (25) m in group 2. To obtain a 90% study power and an alpha error <5%, a sample size of 20 patients completing the study was required in each group. To obtain this result, we estimated an allocation sample size of 50 patients considering a 20% drop-out rate.
Differences between groups were evaluated by unpaired t-test whereas pre-to-post ET differences within each group were evaluated by paired t-test. Effect size for each outcome measure was calculated by Cohen's d. 27 The correlations between changes in primary outcome and baseline variables and in pre-topost ET changes were performed using Pearson's correlation. completed the study. Table 1 shows the demographic, anthropometric and clinical characteristics of these patients and Table 2 shows LTOT and NIV settings. There was no significant baseline difference between groups or between the 25 patients from Lumezzane and the 17 patients from the other centres. 
RESULTS
NIV settings during training
Training intensity
There was no significant difference in maximal training intensity between the groups (38.8 (16.1) vs 42.3 (26. 3) watts in groups 1 and 2, respectively (P = 0.6416)). No major side effects were recorded, whereas hypertension, fatigue and dizziness were recorded in 15% and 17% patients in groups 1 and 2 respectively, without any significant difference between groups (P = 0.8597).
Primary outcome
As shown in Figure 2A Figure 2B after training, 6MWD improved significantly in both RTD and COPD patients without any significant differences between control and NIV groups.
Secondary outcomes
Only pre-to-post ET changes in endurance time were significantly different between the two groups (Table 3) , mainly due to COPD patients (pre-to-post ET change: 564 AE 630 s, P = 0.032 vs 998 AE 1311 s, P = 0.298 in RTD patients). Sixty-eight percent of patients in group 1 and 31% of controls showed an increased endurance time more than the reported MID of 200 s (P = 0.063). 28 Other post-ET changes were not different between groups. In both groups, Peak watts and Borg dyspnoea improved significantly, whereas MIP, MEP and leg fatigue improved significantly only in group 1. MRF-28 significantly improved only in controls (Table 3) . 
Relationships between outcomes
A small, albeit significant relationship was found between changes (Δ, pre-to-post rehabilitation change) in endurance time and Peak watts (R: 0.3872, P = 0.0418), while no significant relationship was found between Δ endurance time and Δ 6MWD or between Δ Peak watts and Δ 6MWD. The Δ 6MWD was inversely related to baseline 6MWD (R: −0.4038, P = 0.0080) and directly related to the presence of RTD (R: 0.3447, P = 0.0254). The Δ endurance time was positively related to the use of NIV during training (R: 0.4175, P = 0.0271).
DISCUSSION
In patients with CRF on long-term nocturnal NIV and LTOT, the addition of NIV during ET sessions did not result in any additional improvement in 6MWD, whereas a significantly greater improvement in cycle endurance time was seen. The incremental exercise test and dyspnoea improved significantly in both groups. Only in group 1 was an improvement in respiratory muscle function and leg fatigue observed, whereas HRQL significantly improved only in controls. 'Acute' use of NIV during exercise reduces the work of breathing and dyspnoea, increasing exercise tolerance in COPD patients as well as in RTD patients. 3, 4, 12, 29 One randomized controlled study 30 found no additional benefit from NIV use during ET, on exercise tolerance, dyspnoea or HRQL compared with ET alone. In contrast, another study 31 found that after a period of NIVassisted training, mean training intensity and peak work rate were higher than after unassisted training. The study by Bianchi et al. 30 recruited milder patients and used lower levels of ventilatory support than the study by Hawkins et al., 31 differences which may have contributed to the conflicting findings of these studies. In another study, 32 COPD patients were randomized into three groups for a 12-week intervention: ET alone, NIV alone and combined treatment. All measures of exercise capacity improved after training alone and the combined treatment, with inflammatory markers improving only with the combined treatment. 32 Another study 33 showed that 20 cm H 2 O IPAP during treadmill walking in patients with severe kyphoscoliosis increased endurance time, pattern of breathing and oxygenation, while reducing the perception of leg muscle fatigue and dyspnoea as compared with unassisted exercise. 33 The effects of long-term nocturnal NIV on 6MWD are controversial. A recent meta-analysis 34 concluded that treatment effects for 6MWD after 3 months were modest (27.7 m). Severe stable COPD patients undergoing home nocturnal NIV and daytime ET showed a significant improvement in exercise capacity and HRQL compared with patients undergoing ET alone. [7] [8] [9] In chronic hypercapnic COPD under long-term ventilatory support, NIV can also be administered during walking, resulting in improved oxygenation, 13 decreased dyspnoea and increased walking distance. 14 ET has also been recommended in kyphoscoliosis patients receiving nocturnal home mechanical ventilation resulting in beneficial effects on exercise capacity, muscle strength, dyspnoea and HRQL. 35 In patients with restrictive disorders, ET including NIV was shown to be effective 12 and feasible at home.
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The discrepancy between the results of 6MWD and endurance tests found in this study is not surprising. Simple field tests like 6-min walking test (6MWT) are widely used to assess the effects of pharmacological and non-pharmacological interventions, although the physiological information gathered is limited. In COPD, endurance tests are more responsive to pharmacological and non-pharmacological interventions than either the incremental tests or the 6MWD test. 36 The 6MWD test might not be the best outcome measure for this study. Walking training with NIV might be more likely to have an effect on walking distance compared with cycling. Indeed, in our study, training and endurance time tests were performed using cycle ergometry explaining at least in part the lack of improvement in 6MWD as compared with the improvement observed in cycle endurance time.
Major barriers to NIV use as an adjunct to ET include lack of confidence around the ventilator model, setting, portability, battery duration, weight of the equipment and time required to set up therapy. 3, 37 Drop-out rates from NIV-aided ET sessions have been described: 7.1% in the study by Borghi-Silva et al., 38 and 28% in the study by Bianchi et al. 30 In the present study, the drop-out rate in group 1 was 19% as compared with 14% in controls, but only two (7.6%) patients refused the protocol due to training or ventilator/mask intolerance.
Previous literature has demonstrated potential problems related to the NIV interface. 30, 37 It is reasonable that the usual interface and ventilator modality used at home could be the most comfortable one when tested during training. A practical implication of the present study suggests the possibility of using the patient's usual home ventilator during training without any additional equipment costs for the healthcare system. Although the suitability of widely available 'home' ventilators to meet the high ventilatory needs of exercise has been questioned, the increasing sophistication and capacity of many of these devices and the accumulating evidence of benefit suggest their potential usefulness. Therefore, the present study shows that NIV during ET using the same settings as nocturnal NIV is feasible and safe without any additional costs for ventilators. However, this study design may not be optimal in adjusting NIV to breathing mechanics during exercise.
A major limitation of the study is that the pressures used may not be sufficient to reduce the work of breathing and unload the respiratory muscles. To improve training and unload the respiratory muscles, the NIV settings targeted should be comparable with other studies. As shown in COPD [39] [40] [41] and in severe kyphoscoliosis, 35 the level of IPAP used during exercise has a direct impact on exercise performance. We did not evaluate whether patient's exercise responders to NIV was pressure related and we did not perform measurements of work of breathing. Therefore, we cannot be sure whether the pressures applied were enough to reduce the work of breathing. Nevertheless, comfort is an important criterion in performing NIV in an awake patient who may otherwise not tolerate NIV. Furthermore, it has been reported that, at least in resting conditions, setting the ventilator on comfort basis can unload the respiratory muscle effectively. 42 No data are available of patient-ventilator interaction during exercise or subjective adaptation to training sessions.
Home devices may not be appropriate to use during exercise, as the capacity of the device may not be great enough during periods of high ventilatory demand. Without external validation of device performance during exercise (e.g. external manometer), we cannot be sure the device was able to pressurize, reach and maintain the preset pressures during ET.
Finally, the length (weeks) of the programme may be not have been sufficient to provide improvements in 6MWD.
In conclusion, in CRF patients under long-term NIV and LTOT, the addition of NIV during ET was feasible and improved the cycle endurance time but did not significantly improve the 6MWD compared with ET alone. 
